American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies
06 juil. 2023 07h00 HE
|
COMPASS Pathways
New code will facilitate reimbursement for psychedelic therapy in the US, if approvedCOMPASS Pathways to hold webinar on new code on Tuesday, July 11, 8:00 am EDT (1:00 pm BST) LONDON, July 06, 2023...
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
05 juil. 2023 07h00 HE
|
COMPASS Pathways
LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today...
COMPASS Pathways to participate in upcoming Cantor Fitzgerald and HC Wainwright investor conferences
16 juin 2023 07h00 HE
|
COMPASS Pathways
LONDON, June 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways' key patents upheld by the US Patent and Trademark Office
06 juin 2023 08h00 HE
|
COMPASS Pathways
PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).In June...
COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer
31 mai 2023 08h30 HE
|
COMPASS Pathways
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today...
COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference
26 mai 2023 16h00 HE
|
COMPASS Pathways
LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023
26 mai 2023 07h00 HE
|
COMPASS Pathways
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study,...
COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights
11 mai 2023 07h00 HE
|
COMPASS Pathways
LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program underway, patients have been treated in both trialsCPT® III code for in-person psychedelic therapy support...
COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023
03 mai 2023 16h01 HE
|
COMPASS Pathways
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
American Medical Association to Issue First New Code for Psychedelic Therapies
02 mai 2023 07h00 HE
|
COMPASS Pathways | MAPS Public Benefit Corporation
LONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based...